• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in this journal  Topic Collections  • Informatics/ Internet in Medicine  • Internet  • Health Care Reform  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Intern Med. 2009;169(21):2024-2030.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The United States has witnessed dramatic changes in the marketing of prescription drugs over the past decade. From one perspective, patients, exposed to a dramatic increase in direct-to-consumer (DTC) promotion of prescription medications,¹ are now "consumers" of health care. The pharmaceutical industry suggests that this promotion helps patients make more informed choices.² However, observers have questioned the benefits of DTC marketing and the balance of associated risk and benefit information.^3-4

As part of the 1997 decision to relax restrictions on broadcast advertisement of prescription drugs, the Food and Drug Administration (FDA) allowed advertisers to refer patients to Web sites for product labeling information.⁵ Indeed, the Internet has become a popular health care resource; 1 in 4 US citizens has searched it for prescription drug information⁶ and consumers consult it more frequently than their physicians.⁷ In a new type of marketing that capitalizes on the informational role of the Internet, manufacturers . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

It Is Time for Food and Drug Administration Reform
Roy Guharoy
Arch Intern Med. 2010;170(8):737.
EXTRACT | FULL TEXT  

RELATED ARTICLES

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2009;169(21):1944.
FULL TEXT  

Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid
Michael R. Law, Stephen B. Soumerai, Alyce S. Adams, and Sumit R. Majumdar
Arch Intern Med. 2009;169(21):1969-1974.
ABSTRACT | FULL TEXT  

Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Joseph S. Ross, David Madigan, Kevin P. Hill, David S. Egilman, Yongfei Wang, and Harlan M. Krumholz
Arch Intern Med. 2009;169(21):1976-1985.
ABSTRACT | FULL TEXT  

Bringing the FDA's Information to Market: Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"
Steven Woloshin and Lisa M. Schwartz
Arch Intern Med. 2009;169(21):1985-1987.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Sources and Popularity of Online Drug Information: An Analysis of Top Search Engine Results and Web Page Views
Law et al.
The Annals of Pharmacotherapy 2011;45:350-356.
ABSTRACT | FULL TEXT  

It Is Time for Food and Drug Administration Reform
Guharoy
Arch Intern Med 2010;170:737-737.
FULL TEXT  

Bringing the FDA's Information to Market: Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"
Woloshin and Schwartz
Arch Intern Med 2009;169:1985-1987.
FULL TEXT